The FDA said an inspection conducted at the facility this year revealed operations that didn't meet the FDA's or Actavis' standards for good manufacturing practices.

Actavis Totowa is voluntarily recalling the products from the pharmacy and retail levels, which includes wholesalers and hospitals, as a precautionary measure.

The FDA said the action isn't prompted by health hazards and patients who may have the medicines in their possession should continue to take them since the risk of suddenly stopping needed medication might place patients at risk.

The voluntary action is limited to Actavis Totowa products and products manufactured in other Actavis facilities are not affected.

A listing of the recalled genetic drugs is available at http://www.actavis.us/en/media+center/newsroom/articles/Actavis+Totowa+Recall.htm.